Nanoparticle vaccine produces virus-neutralising antibodies: Researchers

Scientists have developed a COVID-19 vaccine candidate, which according to them produces “extremely high levels” of protective antibodies in animal models, PTI reported. This may lead to a novel therapeutic that can help curb the impact of the virus.

Researchers, including those from the University of Washington (UW) School of Medicine in the US, said that the nanoparticle vaccine produces virus-neutralising antibodies in much higher levels than that of people who have recovered from COVID-19.

The study noted that the potential vaccine develops ten times as much antibodies in mice even at a six-fold lower vaccine dose, and also shows a strong B-cell immune response after administration, which can be critical for a durable vaccine effect.

Published in the journal Cell, the study says that when a single nonhuman primate was immunised with the vaccine, the scientists said the candidate therapeutic produced neutralising antibodies targeting multiple different sites on the spike protein of the coronavirus, which it uses to enter human cells.

They said this may ensure protection against mutated strains of the virus, should they arise.

According to the study, the molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response.

“We hope that our nanoparticle platform may help fight this pandemic that is causing so much damage to our world,” said Neil King, a co-author of the study from UW Medicine.

“The potency, stability, and manufacturability of this vaccine candidate differentiate it from many others under investigation,” King said.